|
Michael leverages valuable entrepreneur and investor experience from his more than 25 years of work in the Life Science industry including biotechnology, pharmaceuticals, health services and healthcare information technology. In addition to pursuing Life Science investments for MDV he works to extend the firm's reach into major universities and research centers. Prior to joining MDV, Michael was Managing Director of Jasper Capital and Co-chair of the California Research and Cures Coalition ($3 billion Prop 71 stem cell campaign). He has also held senior management and operations roles including serving as Chairman of OnCare, an oncology practice management company he founded in 1995. Until 1999 he also served as OnCare's Chief Executive Officer, where he guided revenue growth to $100 million in three years. Previously, Michael was Founder and Chief Executive Officer of Axion Inc., a cancer-focused healthcare service company he started in 1987 and sold to Bristol-Myers Squibb in 1996. Axion ranked number four on Inc. Magazine's list of the 500 fastest growing private companies in America for the five years ending 1994. Michael was also a recipient of Inc. Magazine's 1995 Entrepreneur of the Year Award. Prior to his tenure with Axion, Michael was a partner in the venture capital firm Sevin Rosen Funds, where he was responsible for the firm's investments in the biomedical industry. Michael is a member of the executive committee of the board of trustees of the National Childhood Cancer Foundation, serves as a Board Member of the California Institute for Regenerative Medicine, is on the Harvard Center for Genetics and Genomics Advisory Council, the Personalized Medicine Coalition, and the Advisory Council of the Stanford Neuroscience Institute. Michael is involved as a board member with a number of privately held companies, including Genomic Health, BidShift and eHealth. Michael received a B.A. from Brandeis University and an M.B.A. from Stanford Graduate School of Business. | 